Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rendong Yang

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Yeung Ho, David W Hillman, et al.
Nature Communications|November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancerMeixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Nature Genetics|July 15, 2020
The DNA methylation landscape of advanced prostate cancerShuang G Zhao, William S Chen, Haolong Li, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone ResistanceManish Kohli, Yeung Ho, David W Hillman, et al.
Nature Communications|November 5, 2021
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancerMeixia Che, Aashi Chaturvedi, Sarah A Munro, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Nature Genetics|July 15, 2020
The DNA methylation landscape of advanced prostate cancerShuang G Zhao, William S Chen, Haolong Li, et al.
Pageof 7